Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Nat Neurosci. 2009 Aug 2;12(9):1114–1120. doi: 10.1038/nn.2361

Table 1.

Effects of partial agonists on single GluN1/GluN2A channel currents

Agonists GluN1/GluN2 reported efficacy (%) amplitude (pA) Po * MOT (ms) MCT (ms) n period analyzed (min) events analyzed
Glu/Gly 100 9.1 ± 0.6 0.64 ± 0.06 11.2 ± 1.1 6.4 ± 1.7 5 190 1,256,063
Glu/DCS 75b, 93c 9.2 ± 0.4 0.45 ± 0.11 8.4 ± 1.4 12 ± 3 5 109 438,502
Glu/Ala 79d 9.5 ± 0.4 0.27 ± 0.04 5.3 ± 0.6 14 ± 2 6 165 941,880
Glu/ACPC 80a 10.0 ± 0.3 0.27 ± 0.04 5.0 ± 0.8 12 ± 2 11 187 1,810,577
Glu/ACBC 40a 10.0 ± 0.2 0.07 ± 0.02 3.8 ± 0.6 39 ± 12 5 62 99,860
HCA/Gly 86e 10.0 ± 0.5 0.29 ± 0.06 4.7 ± 0.7 15 ± 3 10 287 1,791,508
SYM/Gly 72e 10.0 ± 0.6 0.36 ± 0.09 5.7 ± 0.9 13 ± 3 5 98 554,762
HQA/Gly 75e 10.2 ± 0.5 0.25 ± 0.04 5.8 ± 0.7 18 ± 2 5 217 997,465
QA/Gly 20f, 60g 10.0 ± 0.6 0.13 ± 0.06 6.2 ± 1.0 218 ± 87 8 165 328,578

References are: a) Inanobe 2005, b) Sheinen 2001, c) Priestley 1995, d) Chen 2008, e) Erreger 2007, f ) Blanke 2008, g) de Cavalho 1996.

*

Open probability was calculated as the fractional occupancy of the open state when fitting the entire sequence of events to kinetic models having five closed and one open states (5C1O).

HHS Vulnerability Disclosure